Patents Assigned to Merck Frosst Canada, Inc.
  • 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
    Patent number: 5225421
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti asthmatic, anti allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: July 6, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Howard E. Morton, Rejean Fortin, Yvan Guindon
  • (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5221678
    Abstract: Compounds having the Formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: June 22, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Joseph G. Atkinson, John W. Gillard, Erich L. Grimm
  • Quinoline-containing ketoacids as leukotriene antagonists
    Patent number: 5212180
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: May 18, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Michel L. Belley
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5204344
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: February 5, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, John Gillard, Richard Frenette
  • Hetaryl styryl quinolines as leukotriene inhibitors
    Patent number: 5204358
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: April 20, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Jacques-Yves Gauthier, Michel L. Belley
  • Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5202321
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: April 13, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John H. Hutchinson, Yves Girard, Rejean Fortin, Dwight MacDonald, John Scheigetz, Daniel Delorme, Michel Therien, Pierre Hamel
  • (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5190968
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 30, 1991
    Date of Patent: March 2, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, John H. Hutchinson
  • (Quinolin-2-ylmethoxy)Heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5187180
    Abstract: (Quinolin-2-ylmethoxy)Heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes useful in the treatment of asthma and eye inflamation.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: February 16, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventor: John W. Gillard
  • 5-lipoxygenase activating protein
    Patent number: 5182367
    Abstract: An 18kD protein (FLAP) has been isolated from rat and human cells which is necessary for production of leukotrienes from arachidonic acid in mammalian cells containing 5-lipoxygenase. The gene (cDNA) encoding for FLAP has also been produced.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: January 26, 1993
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Jacques-Yves Gauthier, Jillian F. Evans, Rejean Fortin, Yvan Guinon, Richard A. F. Dixon, Douglas K. Miller
  • Quinoline-substituted chromans and related compounds as leukotriene antagonists
    Patent number: 5149703
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: September 22, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Claude Dufresne
  • Synthesis of chiral thioacetals and thioethers
    Patent number: 5136034
    Abstract: Thioacids, thiols, an acid, and an aldehyde are used to produce chiral thioacetals of the general formula. ##STR1## The compounds are leukotriene antagonists.
    Type: Grant
    Filed: October 5, 1990
    Date of Patent: August 4, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Michel Therien, Jacques-Yves Gauthier, Robert Zamboni, Michel L. Belley
  • Leukotriene antagonists
    Patent number: 5135940
    Abstract: Compounds of the Formulae: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: August 4, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Joshua Rokach, Rejean Fortin, Christiane Yoakim, Yvan Guindon
  • 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
    Patent number: 5132319
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: July 21, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Pierre Hamel, Daniel Delorme, Rejean Fortin
  • Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
    Patent number: 5128364
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: July 7, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Pierre Hamel
  • Triphenyl methanethiol-35S
    Patent number: 5118858
    Abstract: Disclosed herein are /.sup.35 S/-labelled compound of the formula (I):(C.sub.6 H.sub.5).sub.3 C.sup.35 SHand processes therefor. This Compound (I) is useful as an intermediate for the introduction of sulfur isotope into a variety of compounds. For example, it is useful in the introduction of sulfur isotope into important compounds such as 6-mercaptopurine, 5-[3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl]-8-dimethylcarbamyl-4,6-dith ioactanoic acid, a potent antagonist of leukotriene D.sub.4 ; thiophosphoric acid derivatives, photo-affinity reagents and the like.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: June 2, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Haydn W. R. Williams, Robert N. Young, Robert J. Zamboni
  • Diarylstrylquinoline diacids and pharmaceutical compositions thereof
    Patent number: 5104882
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: April 14, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Jacques-Yves Gauthier, Michel L. Belley
  • Quinoline ether alkanoic acids
    Patent number: 5102881
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: April 7, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert Zamboni, Petpiboon Prasit, Robert N. Young
  • Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
    Patent number: 5093356
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: January 16, 1990
    Date of Patent: March 3, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Pierre Hamel, Daniel Delorme
  • Radiopharmaceutical bacteriostats
    Patent number: 5093105
    Abstract: Benzalkonium chloride and benzethonium chloride are each useful in radiopharmaceutical preparations as bacteriostatic agents which are compatible with anti-oxidants.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: March 3, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard J. Flanagan, Daniel Tartaglia
  • 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
    Patent number: 5091533
    Abstract: Compounds of the formula: ##STR1## where R.sup.2 contains certain aryls or heteroaryls are effective leukotriene inhibitors.
    Type: Grant
    Filed: March 12, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Claude Dufresne, Brian Fitzsimmons, deceased, Maryann Fitzsimmons, Heir, Yvan Guindon, Cheuk K. Lau, Joshua Rokach, John Schiegetz, Michel Therien, Robert N. Young